On March 11, 2022 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that management will participate in the Oppenheimer & Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17 (Press release, Cellectis, MAR 11, 2022, View Source [SID1234609973]). Details for both presentations are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Annual Healthcare Conference:

Date: March 16

Time: 4:00pm EST

Webcast: View Source;page=clls&url=View Source

Barclays Global Healthcare Conference:

Date: March 17

Time: 9:30am EST

Webcast: View Source;tp_key=0d6c4a2a9d&tp_special=8

Live webcasts of these events and a replay of these webcasts will be available under the "Events and Webcasts" section on the Investor page of the of the Company’s at website: View Source